Fed. Circ. Won't Consider Sales Ban On Generic Latisse
The Federal Circuit on Friday refused to reconsider its decision to lift an injunction on generic versions of Allergan Inc.'s eyelash growth stimulant Latisse after previously ruling that two patents covering...To view the full article, register now.
Already a subscriber? Click here to view full article